Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07110454 · ClinicalTrials.gov registry record
Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up
A clinical trial of Epilepsy and Epilepsy (Treatment Refractory), sponsored by Epiminder America.
- Recruiting
- Registry status
- 210
- Enrollment target
- 7
- Study locations
NCT07110454 is a study of Epilepsy and Epilepsy (Treatment Refractory) that is actively recruiting participants, run by Epiminder America. The registered enrollment target is 210 participants, below the 951-participant average among 160 other Epilepsy trials with a reported enrollment target (78% lower). The trial reports 7 study locations across 7 states.
The verdict
NCT07110454, a study of Epilepsy and Epilepsy (Treatment Refractory), is actively recruiting participants, sponsored by Epiminder America.
- RECRUITING
- Registry status
- 210 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this research is to address the challenges of correctly monitoring, managing, and diagnosing epilepsy in participants whose seizures are not well captured by standard electroencephalography (EEG) tests and who cannot use or are not able to use more standard monitoring techniques. This research is being done to understand how the Minder System helps physicians make decisions about participant's epilepsy treatment after an actionable event. The Minder System was granted De Novo classification by the U.S. Food and Drug Administration (FDA) and is not investigational. Participants that have completed the DETECT study and received the Minder System previously will consent to join this long-term follow-up observational study. The study will collect information about general wellbeing, use of healthcare services, and experience using the Minder data over time to support long-term epilepsy care. All participants will continue to be followed by their treating physician and undergo assessments and visits every six (6) months until two (2) years after receiving the Minder device.
Conditions Studied
Interventions
- DEVICE Previous receipt of the Minder System (implantable continuous electroencephalographic (EEG) monitoring (iCEM) system)
Study Locations (7)
Arizona
- Mayo Clinic - Arizona - Phoenix
Connecticut
- Yale School of Medicine - New Haven
Florida
- Mayo Clinic - Florida - Jacksonville
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Minnesota
- Mayo Clinic - Rochester - Rochester
Missouri
- Washington University - St Louis
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2026-06 |
| Est. Completion | 2029-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07110454
The ClinicalTrials.gov registry entry for NCT07110454 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 951-participant average among 160 other Epilepsy trials with a reported enrollment target (78% lower). The listed sponsor is Epiminder America, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which Previous receipt of the Minder System (implantable continuous electroencephalographic (EEG) monitoring (iCEM) system) is the first listed.
NCT07110454 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Arizona, Connecticut, Florida.
Frequently Asked Questions
What is clinical trial NCT07110454 about?
NCT07110454 is a clinical study titled "Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up". The purpose of this research is to address the challenges of correctly monitoring, managing, and diagnosing epilepsy in participants whose seizures are not well captured by standard electroencephalography (EEG) tests and who cannot use or are not able to use more standard monitoring techniques. This...
What is the current status of trial NCT07110454?
This trial is currently recruiting. The enrollment target is 210 participants. The study started on 2026-06. Estimated completion is 2029-01.
What conditions does trial NCT07110454 study?
This clinical trial studies the following conditions: Epilepsy, Epilepsy (Treatment Refractory).
What interventions are being tested in trial NCT07110454?
The interventions under investigation include: Previous receipt of the Minder System (implantable continuous electroencephalographic (EEG) monitoring (iCEM) system) (DEVICE).
Who is sponsoring clinical trial NCT07110454?
This trial is sponsored by Epiminder America, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07110454 being conducted?
This trial has 7 study locations across Arizona, Connecticut, Florida, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Retrospective Survey-based Multicenter Study to Delineate the Molecular and Phenotypic Spectrum of Epilepsy-dyskinesia Syndromes
RECRUITING
-
SeizEAR Safety Study
RECRUITING · NA
-
Physiological-based Pharmacokinetics Approach to Medication Exposure During Pregnancy and Breastfeeding
RECRUITING
-
Tumor Related Epilepsy
RECRUITING
-
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
RECRUITING · Phase 1
-
Understanding Prefrontal and Medial Temporal Neuronal Responses to Algorithmic Cognitive Variables in Epilepsy Patients
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.